PMN vs TRBG Comparison

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.